What is Jaguar Health, Inc.'s earnings per share (EPS)?

Jaguar Health, Inc. (JAGX) reported diluted earnings per share of -$0.02 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jaguar Health, Inc. (JAGX) Financials

JAGX

Trailing 12 months to June 30, 2026

Revenue $27.8M +135.5% YoY

Net Income $16.7M +863.5% YoY

EPS (Diluted) -$35.94 +96.7% YoY

Operating Cash Flow -$6.7M +75.8% YoY

Market Cap $1.6M as of Sep 12, 2026

Price / Sales 0.1x on $27.8M revenue, trailing 12 months to June 30, 2026

Price / Earnings 0.1x on $16.7M net income, trailing 12 months to June 30, 2026

Price / Book 0.3x on $4.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 19, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JAGX SEC filings page.

Jaguar Health, Inc. (JAGX) reported $27.8M in revenue over the twelve months to Jun 30, 2026, up 135.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI JAGX FY2025 2026-08-29

Development-stage spending converts near-total gross margin into persistent operating losses and greater balance-sheet dependence on financing.

In FY2025, gross margin reached 99.2% as cost of revenue fell to $97K, yet operating loss widened to $45.9M. That margin step-up did not create operating leverage: R&D alone reached $25.0M, so development spending—not product cost—is absorbing the revenue base.

Revenue was $11.5M while operating cash flow was -$23.7M in FY2025; this cash-conversion gap means reported sales did not fund the operating cost structure. Reported liquidity measured just 0.5 months of the latest annual operating outflow, while financing provided the offset.

The balance sheet moved from $6.5M of equity in FY2024 to -$18.7M in FY2025, showing that accumulated losses materially changed the funding structure. The current ratio fell from 1.6x to 0.5x, meaning short-term obligations became heavier relative to current assets.

Financial Health Signals

Financial Health Score 32/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Jaguar Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Jaguar Health, Inc. held $968K in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $23.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Jaguar Health, Inc. scores 3/100 among other emerging companies.

Dilution

Not available for Jaguar Health, Inc., and counted as zero in the overall score.

R&D Intensity

Jaguar Health, Inc. spent $25.0M on research and development in fiscal year 2025, which was 43.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Jaguar Health, Inc. scores 73/100 among other emerging companies.

Revenue Progress

Jaguar Health, Inc. reported revenue of $11.5M in fiscal year 2025, against $11.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Jaguar Health, Inc. scores 54/100 among other emerging companies.

Burn Trend

Jaguar Health, Inc.'s operations used $23.7M of cash in fiscal year 2025, against $29.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Jaguar Health, Inc. scores 60/100 among other emerging companies.

Balance Sheet

Jaguar Health, Inc.'s cash, cash equivalents and investments came to $968K at the end of fiscal year 2025, against $57.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Jaguar Health, Inc. scores 4/100 among other emerging companies.

Altman Z-Score Distress

-18.88

Jaguar Health, Inc. scores -18.88, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.6M) relative to total liabilities ($57.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Jaguar Health, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Jaguar Health, Inc. reported a net loss of $54K while operations used $23.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Jaguar Health, Inc. reported an operating loss of $45.9M against $67K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.2M

YoY-58.9%

QoQ-94.0%

Jaguar Health, Inc. generated $1.2M in revenue in Q2 2026. This represents a decrease of 58.9% from the same quarter a year earlier. Against the prior quarter it is down 94.0%.

EBITDA

-$7.1M

YoY+5.4%

QoQ-166.9%

Jaguar Health, Inc.'s EBITDA was -$7.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is down 166.9%.

Net Income

-$12.8M

YoY-23.0%

QoQ-246.8%

Jaguar Health, Inc. reported -$12.8M in net income in Q2 2026. This represents a decrease of 23.0% from the same quarter a year earlier. Against the prior quarter it is down 246.8%.

EPS (Diluted)

-$15.70

QoQ-15.4%

Jaguar Health, Inc. earned -$15.70 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 15.4%.

Cash & Balance Sheet

Cash & Debt

$3.8M

YoY+71.6%

QoQ-48.0%

5Y CAGR-29.7%

10Y CAGR-0.2%

Jaguar Health, Inc. held $3.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

Diluted avg 809,122

Jaguar Health, Inc. had a weighted average of 809,122 diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

15.8%

YoY-80.9pp

QoQ-78.5pp

Jaguar Health, Inc.'s gross margin was 15.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 80.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 78.5 percentage points.

Return on Equity

-260.2%

YoY-108.9pp

Jaguar Health, Inc.'s ROE was -260.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 108.9 percentage points from the same quarter a year earlier.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$3.3M

YoY+2.2%

QoQ-15.1%

Jaguar Health, Inc. invested $3.3M in research and development in Q2 2026. This represents an increase of 2.2% from the same quarter a year earlier. Against the prior quarter it is down 15.1%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

JAGX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JAGX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$27.8M	$11.5M-1.5%	$11.7M+19.8%	$9.8M-18.4%	$12.0M+175.8%	$4.3M-53.8%	$9.4M+62.5%	$5.8M+30.8%	$4.4M+1.3%	$4.4M+2981.6%	$142K-45.2%	$258K	$0
Cost of Revenue	$1.7M	$97K-95.0%	$2.0M-4.0%	$2.0M+0.9%	$2.0M-13.5%	$2.3M-28.9%	$3.3M-14.0%	$3.8M+38.0%	$2.8M+214.1%	$880K+1594.2%	$52K-57.9%	$123K	N/A
Gross Profit	$26.1M	$11.4M+17.3%	$9.7M+26.0%	$7.7M-22.3%	$9.9M+396.4%	$2.0M-67.2%	$6.1M+211.6%	$2.0M+18.7%	$1.7M-52.6%	$3.5M+3786.7%	$90K-33.6%	$135K	N/A
R&D Expenses	$25.2M	$25.0M+50.9%	$16.5M-11.0%	$18.6M+5.4%	$17.6M+17.0%	$15.1M+135.1%	$6.4M+10.2%	$5.8M+12.9%	$5.2M+20.7%	$4.3M-40.8%	$7.2M+11.3%	$6.5M+53.4%	$4.2M
SG&A Expenses	$17.6M	$18.6M+14.2%	$16.3M-1.5%	$16.6M-7.2%	$17.9M+4.5%	$17.1M+18.9%	$14.4M+6.6%	$13.5M+10.0%	$12.3M+9.2%	$11.2M+88.0%	$6.0M+12.1%	$5.3M+30.4%	$4.1M
Operating Income	-$25.9M	-$45.9M-48.9%	-$30.8M+10.1%	-$34.3M+0.4%	-$34.4M+15.5%	-$40.7M-52.8%	-$26.6M+7.9%	-$28.9M+6.1%	-$30.8M+10.0%	-$34.2M-152.1%	-$13.6M-9.2%	-$12.4M-49.7%	-$8.3M
EBITDA	N/A	-$44.0M-52.1%	-$28.9M+10.4%	-$32.3M+0.5%	-$32.4M+16.8%	-$39.0M-56.5%	-$24.9M+8.4%	-$27.2M+7.8%	-$29.5M+12.4%	-$33.7M-148.6%	-$13.5M-8.8%	-$12.4M	N/A
Interest Expense	$998K	$67K-71.0%	$231K-96.4%	$6.4M-49.8%	$12.7M+51.1%	$8.4M+201.6%	$2.8M-51.3%	$5.7M+118.0%	$2.6M+117.3%	$1.2M+22.7%	$986K-70.3%	$3.3M+860.6%	$345K
Income Tax	N/A	$0	$0	$0	$0	$0	$0-100.0%	$10K	N/A	-$13.2M	N/A	N/A	N/A
Net Income	$16.7M	-$54K-37.6%	-$39K+6.3%	-$42K+13.4%	-$48K+8.0%	-$53K+99.8%	-$33.8M+12.3%	-$38.5M-19.9%	-$32.1M-46.3%	-$22.0M-49.1%	-$14.7M+9.6%	-$16.3M-89.2%	-$8.6M
EPS (Basic)	N/A	-$22.97+82.4%	-$130.69+95.1%	-$2678.17-7302.3%	-$36.18+59.0%	-$88.22-2840.7%	-$3.00	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$35.94	-$0.02	-$0.13	-$2.68	-$0.04	-$0.09	-$3.00	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	294,534	15,421	1M	596,154	13M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.2M-58.9%	$20.3M+815.6%	$3.2M-7.8%	$3.1M-0.8%	$3.0M+9.5%	$2.2M-5.8%	$3.5M	$3.1M+10.5%
Cost of Revenue	$1.0M+962.9%	$1.2M+124.9%	-$1.0M-288.0%	$532K-1.7%	$97K-77.3%	$515K+19.8%	$557K	$541K+5.3%
Gross Profit	$194K-93.3%	$19.1M+1025.0%	$4.3M+45.1%	$2.6M-0.6%	$2.9M+25.6%	$1.7M-11.6%	$3.0M	$2.6M+11.7%
R&D Expenses	$3.3M+2.2%	$3.9M+5.3%	$14.3M+215.7%	$3.7M-9.5%	$3.3M-10.6%	$3.7M-13.5%	$4.5M	$4.0M-33.5%
SG&A Expenses	$4.5M-5.9%	$4.1M-16.1%	$4.9M+26.6%	$4.1M+9.5%	$4.7M+9.6%	$4.9M+11.8%	$3.9M	$3.8M+6.9%
Operating Income	-$7.6M+5.1%	$10.2M+208.1%	-$21.2M-160.4%	-$7.2M+0.3%	-$8.0M-11.3%	-$9.4M-14.7%	-$8.2M	-$7.3M+17.4%
EBITDA	-$7.1M+5.4%	$10.7M+219.2%	-$20.8M-170.4%	-$6.8M+0.4%	-$7.5M-11.5%	-$8.9M-15.9%	-$7.7M	-$6.8M+18.0%
Interest Expense	$161K+1173.3%	$699K+1348.2%	$132K+220.0%	$6K+103.7%	-$15K+86.1%	-$56K-109.2%	-$110K	-$162K-132.4%
Income Tax	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Net Income	-$12.8M-23.0%	$8.7M+183.4%	$30.3M+6.3%	-$9.5M+3.6%	-$10.4M-9.6%	-$10.5M-13.4%	$28.5M	-$9.9M-26.7%
EPS (Basic)	-$15.70+95.6%	-$13.60+97.7%	-$0.36+99.7%	-$6.28+76.1%	-$358.94-13394.0%	-$584.45-570.9%	-$125.80+95.1%	-$26.29-16.8%
EPS (Diluted)	-$15.70	-$13.60+97.7%	-$0.36+99.7%	-$6.28	-$358.94	-$584.45	-$125.80+95.1%	-$26.29-16.8%
Diluted Shares (Avg)	809,122	515,788+2780.9%	N/A	2M	28,994	17,904	N/A	374,805+8.4%

JAGX Balance Sheet

JAGX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$38.3M-28.3%	$53.4M+5.2%	$50.8M+7.0%	$47.5M-10.9%	$53.3M+24.3%	$42.8M+17.7%	$36.4M-11.3%	$41.0M-5.9%	$43.6M+1124.5%	$3.6M-71.3%	$12.4M+180.7%	$4.4M
Current Assets	$20.3M-36.8%	$32.2M+15.1%	$28.0M+25.3%	$22.3M-21.5%	$28.4M+59.8%	$17.8M+86.9%	$9.5M+16.8%	$8.1M+114.5%	$3.8M+48.7%	$2.6M-69.8%	$8.5M+138.3%	$3.5M
Cash & Equivalents	$968K-87.9%	$8.0M+23.7%	$6.5M+18.3%	$5.5M-67.9%	$17.1M+110.8%	$8.1M+131.5%	$3.5M+36.1%	$2.6M+393.2%	$521K-45.2%	$951K-87.6%	$7.7M+810.7%	$845K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$8.6M-16.9%	$10.3M+12.6%	$9.2M+30.8%	$7.0M+43.3%	$4.9M+76.1%	$2.8M+30.7%	$2.1M-36.3%	$3.3M+61.2%	$2.1M+402.2%	$413K+79.6%	$230K+16.1%	$198K
Accounts Receivable	$1.5M-0.4%	$1.5M-22.4%	$2.0M+4.7%	$1.9M+9.9%	$1.7M-18.5%	$2.1M+24.0%	$1.7M+69.9%	$996K+112.9%	$468K+9322.9%	$5K-91.1%	$56K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5.2M0.0%	$5.2M	$0	N/A	N/A
Total Liabilities	$57.0M+28.3%	$44.4M-3.1%	$45.9M-6.0%	$48.8M+17.9%	$41.4M+61.5%	$25.6M-0.4%	$25.7M-27.8%	$35.7M+35.2%	$26.4M+338.2%	$6.0M-24.8%	$8.0M-36.7%	$12.7M
Current Liabilities	$40.7M+106.3%	$19.7M+40.9%	$14.0M-53.9%	$30.3M+96.1%	$15.5M+17.0%	$13.2M-14.1%	$15.4M-42.3%	$26.7M+73.3%	$15.4M+267.0%	$4.2M+7.3%	$3.9M+12.4%	$3.5M
Non-Current Liabilities	$16.4M-33.9%	$24.7M-22.4%	$31.9M+72.6%	$18.5M-28.8%	$25.9M+108.8%	$12.4M+20.1%	$10.3M+14.9%	$9.0M-18.0%	$11.0M+501.9%	$1.8M-55.5%	$4.1M-55.4%	$9.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$11.0M+504.3%	$1.8M-55.6%	$4.1M	N/A
Total Equity	-$18.7M-387.8%	$6.5M+32.6%	$4.9M+460.3%	-$1.4M-111.5%	$11.9M-31.1%	$17.2M+61.2%	$10.7M+98.3%	$5.4M-68.8%	$17.3M+803.3%	-$2.5M-155.8%	$4.4M+153.4%	-$8.2M
Retained Earnings	-$399.9M-15.4%	-$346.5M-12.4%	-$308.2M-15.5%	-$266.9M-21.6%	-$219.5M-31.5%	-$166.9M-25.4%	-$133.1M-40.8%	-$94.6M-51.5%	-$62.4M-54.3%	-$40.4M-57.3%	-$25.7M-173.1%	-$9.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$34.2M-29.2%	$37.4M-27.3%	$38.3M-28.3%	$49.5M-15.4%	$48.3M-21.5%	$51.5M-7.1%	$53.4M+5.2%	$58.5M+28.8%
Current Assets	$17.5M-37.2%	$20.2M-33.6%	$20.3M-36.8%	$29.4M-19.8%	$27.9M-30.4%	$30.4M-9.7%	$32.2M+15.1%	$36.6M+66.1%
Cash & Equivalents	$3.8M+71.6%	$7.3M+27.9%	$968K-87.9%	$3.5M-73.4%	$2.2M-86.2%	$5.7M-51.2%	$8.0M+23.7%	$13.3M+311.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$7.3M-31.7%	$7.8M-25.9%	$8.6M-16.9%	$10.6M+9.9%	$10.7M+12.2%	$10.6M+17.0%	$10.3M+12.6%	$9.7M+15.5%
Accounts Receivable	$8K-99.3%	$68K-94.4%	$1.5M-0.4%	$1.4M+15.1%	$1.2M-9.7%	$1.2M-19.1%	$1.5M-22.4%	$1.2M-25.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$29.3M-29.3%	$53.2M+10.5%	$57.0M+28.3%	$45.1M+5.2%	$41.4M-2.4%	$48.1M+17.2%	$44.4M-3.1%	$42.9M-2.5%
Current Liabilities	$25.4M-13.1%	$40.7M+44.2%	$40.7M+106.3%	$36.1M+81.8%	$29.2M+52.7%	$28.2M+58.3%	$19.7M+40.9%	$19.9M+59.6%
Non-Current Liabilities	$3.9M-68.0%	$12.5M-37.3%	$16.4M-33.9%	$9.0M-60.9%	$12.2M-47.7%	$19.9M-14.3%	$24.7M-22.4%	$23.0M-27.0%
Total Equity	$4.9M-28.5%	-$15.8M-1997.8%	-$18.7M-387.8%	$4.4M-66.7%	$6.9M-58.5%	$830K-93.0%	$6.5M+32.6%	$13.1M+824.9%
Retained Earnings	-$403.7M-9.9%	-$391.1M-9.6%	-$399.9M-15.4%	-$376.9M-12.0%	-$367.4M-12.4%	-$356.9M-12.5%	-$346.5M-12.4%	-$336.6M-12.5%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

JAGX Cash Flow Statement

JAGX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$6.7M	-$23.7M+19.4%	-$29.4M+11.6%	-$33.2M-0.4%	-$33.1M+5.3%	-$35.0M-128.9%	-$15.3M+25.3%	-$20.5M+10.0%	-$22.7M-131.4%	-$9.8M+31.8%	-$14.4M-0.7%	-$14.3M-167.1%	-$5.4M
Depreciation & Amortization	N/A	$1.9M+0.7%	$1.9M-5.6%	$2.0M+1.6%	$2.0M+15.2%	$1.7M-0.5%	$1.7M-0.6%	$1.7M+31.7%	$1.3M+125.7%	$584K+1130.3%	$47K+821.3%	$5K	N/A
Stock-Based Compensation	N/A	$831K-49.4%	$1.6M-22.3%	$2.1M-36.3%	$3.3M-16.5%	$4.0M+40.7%	$2.8M-5.5%	$3.0M+47.7%	$2.0M+148.4%	$815K+13.5%	$718K-27.6%	$992K+504.4%	$164K
Capital Expenditures	N/A	N/A	$16K	N/A	$77K+1183.3%	$6K-14.3%	$7K	N/A	$7K	N/A	$104K+347.2%	$23K-57.8%	$55K
Free Cash Flow	N/A	N/A	-$29.4M	N/A	-$33.2M+5.1%	-$35.0M-128.8%	-$15.3M	N/A	-$22.7M	N/A	-$14.5M-1.2%	-$14.3M-164.8%	-$5.4M
Investing Cash Flow	N/A	-$41K+82.3%	-$231K	N/A	-$1.7M-27816.7%	-$6K+14.3%	-$7K	N/A	-$7K+99.6%	-$1.6M-165.3%	$2.4M	N/A	N/A
Financing Cash Flow	$11.3M	$23.7M-24.1%	$31.2M-8.8%	$34.2M+47.7%	$23.2M-47.2%	$43.9M+125.4%	$19.5M-10.5%	$21.8M-11.3%	$24.5M+129.8%	$10.7M+102.2%	$5.3M	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$30	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$5.3M+13.8%	$8.8M+220.7%	-$5.5M+29.9%	-$4.7M+26.1%	-$6.2M+24.2%	-$7.3M-3.8%	-$7.8M-5.0%	-$6.3M+6.6%
Depreciation & Amortization	$473K-1.0%	$473K-1.3%	$477K-0.2%	$479K+1.1%	$478K+6.9%	$479K-4.4%	$478K-4.8%	$474K-6.0%
Stock-Based Compensation	$171K-38.7%	$155K-48.5%	N/A	$135K-56.5%	$279K-27.2%	$301K-48.2%	N/A	$310K-42.3%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$7.8M	-$6.3M+6.6%
Investing Cash Flow	N/A	N/A	$13K+106.0%	N/A	N/A	N/A	-$215K	$0
Financing Cash Flow	$1.9M-29.9%	-$6.6M-233.2%	$9.8M+245.9%	$6.3M+77.3%	$2.7M-78.9%	$5.0M-59.5%	$2.8M-73.4%	$3.5M+150.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

JAGX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

JAGX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	99.2%+15.9pp	83.3%+4.1pp	79.1%-4.0pp	83.1%+36.9pp	46.2%-18.9pp	65.0%+31.1pp	33.9%-3.4pp	37.4%-42.4pp	79.8%+16.5pp	63.3%+11.1pp	52.2%	N/A
Operating Margin	-398.8%	-263.8%	-351.3%	-287.8%	-939.0%	-283.9%	-501.3%	-698.0%	-785.3%	-9599.8%	-4816.7%	N/A
Net Margin	-0.5%-0.1pp	-0.3%+0.1pp	-0.4%0.0pp	-0.4%+0.8pp	-1.2%	-360.3%	-667.3%	-727.9%	-503.7%	-10410.9%	-6305.2%	N/A
Return on Equity	N/A	-0.6%+0.3pp	-0.9%	N/A	-0.4%+196.1pp	-196.5%+164.5pp	-361.1%+236.1pp	-597.2%-469.9pp	-127.3%	N/A	-370.3%	N/A
Return on Assets	-0.1%-0.1pp	-0.1%0.0pp	-0.1%0.0pp	-0.1%0.0pp	-0.1%+78.8pp	-78.9%+26.9pp	-105.8%-27.5pp	-78.3%-28.0pp	-50.3%+363.1pp	-413.5%-282.2pp	-131.3%+63.5pp	-194.8%
Current Ratio	0.50-1.1x	1.63-0.4x	2.00+1.3x	0.74-1.1x	1.84+0.5x	1.35+0.7x	0.62+0.3x	0.31+0.1x	0.25-0.4x	0.61-1.6x	2.16+1.1x	1.02
Debt-to-Equity	N/A	6.84-2.5x	9.37	N/A	3.49+2.0x	1.49-0.9x	2.41-4.2x	6.62+6.0x	0.64	N/A	0.93	N/A
Asset Turnover	0.30+0.1x	0.220.0x	0.19-0.1x	0.25+0.2x	0.08-0.1x	0.22+0.1x	0.16+0.1x	0.110.0x	0.10+0.1x	0.040.0x	0.020.0x	0.00
FCF Margin	N/A	-251.5%	N/A	-277.5%	-806.8%	-162.9%	N/A	-514.9%	N/A	-10258.4%	-5549.6%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	15.8%-80.9pp	94.3%+17.5pp	132.4%	82.7%+0.2pp	96.7%+12.4pp	76.7%-5.0pp	84.1%	82.6%+0.9pp
Operating Margin	-620.2%	50.2%	-656.6%	-234.8%	-268.8%	-425.5%	-232.5%	-233.7%
Net Margin	-1045.1%	43.0%	937.2%	-308.2%	-349.4%	-472.6%	813.1%	-317.1%
Return on Equity	-260.2%-108.9pp	N/A	N/A	-218.0%-142.8pp	-151.3%-94.0pp	-1260.7%-1182.7pp	439.4%	-75.2%+474.1pp
Return on Assets	-37.4%-15.9pp	23.3%+43.6pp	79.1%+25.7pp	-19.2%-2.4pp	-21.6%-6.1pp	-20.3%-3.7pp	53.4%	-16.9%+0.3pp
Current Ratio	0.69-0.3x	0.50-0.6x	0.50-1.1x	0.81-1.0x	0.95-1.1x	1.08-0.8x	1.63-0.4x	1.84+0.1x
Debt-to-Equity	5.95-0.1x	N/A	N/A	10.35+7.1x	6.02+3.5x	58.01+54.5x	6.84-2.5x	3.27-27.8x
Asset Turnover	0.040.0x	0.54+0.5x	0.080.0x	0.060.0x	0.060.0x	0.040.0x	0.07	0.050.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-223.0%	-204.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$18.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Jaguar Health, Inc. JAGX	FY2025	$11.5M	-$54K	-0.5%	$1.6M	32/100
Quoin Pharmaceuticals, Ltd. American QNRX	FY2025	N/A	-$15.8M	N/A	$13.6M	—
XORTX Therapeutics Inc. XRTX	FY2025	N/A	-$2.7M	N/A	$4.2M	—
Azitra Inc AZTR	FY2025	$0	-$11.0M	N/A	$10.9M	—
GRI Bio, Inc. GRI	FY2025	N/A	-$12.0M	N/A	$4.2M	—
Onconetix, Inc. ONCO	FY2025	$815K	-$14.0M	N/A	$3.3M	—

Where Jaguar Health, Inc. Ranks

Frequently Asked Questions

What is Jaguar Health, Inc.'s annual revenue?

Jaguar Health, Inc. (JAGX) reported $11.5M in total revenue for fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jaguar Health, Inc.'s revenue growing?

Jaguar Health, Inc. (JAGX) revenue declined by 1.5% year-over-year, from $11.7M to $11.5M in fiscal year 2025.

Is Jaguar Health, Inc. profitable?

No, Jaguar Health, Inc. (JAGX) reported a net income of -$54K in fiscal year 2025, with a net profit margin of -0.5%.

What is Jaguar Health, Inc.'s EBITDA?

Jaguar Health, Inc. (JAGX) had EBITDA of -$44.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jaguar Health, Inc.'s gross margin?

Jaguar Health, Inc. (JAGX) had a gross margin of 99.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Jaguar Health, Inc.'s net profit margin?

Jaguar Health, Inc. (JAGX) had a net profit margin of -0.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Jaguar Health, Inc.'s operating cash flow?

Jaguar Health, Inc. (JAGX) recorded an outflow of $23.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Jaguar Health, Inc.'s total assets?

Jaguar Health, Inc. (JAGX) had $38.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Jaguar Health, Inc. spend on research and development?

Jaguar Health, Inc. (JAGX) invested $25.0M in research and development during fiscal year 2025.

What is Jaguar Health, Inc.'s current ratio?

Jaguar Health, Inc. (JAGX) had a current ratio of 0.50 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Jaguar Health, Inc.'s return on assets (ROA)?

Jaguar Health, Inc. (JAGX) had a return on assets of -0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jaguar Health, Inc.'s P/E ratio?

Jaguar Health, Inc. (JAGX) trades at 0.1x earnings, its market capitalization divided by net income of $16.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.6M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Jaguar Health, Inc.'s price-to-sales ratio?

Jaguar Health, Inc. (JAGX) trades at 0.1x sales, its market capitalization divided by revenue of $27.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.6M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Jaguar Health, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Jaguar Health, Inc. (JAGX) held $968K in cash, cash equivalents and investments, and reported an operating cash outflow of $23.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Jaguar Health, Inc.'s debt-to-equity ratio negative or not reported?

Jaguar Health, Inc. (JAGX) has negative shareholder equity of -$18.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Jaguar Health, Inc.'s Altman Z-Score?

Jaguar Health, Inc. (JAGX) has an Altman Z-Score of -18.88, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Jaguar Health, Inc.'s Piotroski F-Score?

Jaguar Health, Inc. (JAGX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jaguar Health, Inc.'s earnings high quality?

Jaguar Health, Inc. (JAGX) reported a net loss of $54K while operations used $23.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Jaguar Health, Inc. cover its interest payments?

Jaguar Health, Inc. (JAGX) reported an operating loss of $45.9M against $67K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Jaguar Health, Inc.?

Jaguar Health, Inc. (JAGX) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.